Lupin subsidiary settles US antitrust case with Humana for $30 Million

The litigation involved multiple civil lawsuits alleging anti-competitive practices and violations of federal

Glenmark Pharmaceuticals reached $37.75 million settlement in antitrust litigation in US

Glenmark USA is named in multiple antitrust and consumer protection lawsuits, including class actions, consolidated in the Eastern District of Pennsylvania, U.S

Natco Pharma and Breckenridge dismissed from antitrust lawsuit

Glenmark Pharmaceuticals USA reaches antitrust settlement with DOJ

The company has entered into a three-year Deferred Prosecution Agreement

Eli lilly goes all-in on vaccines with $3b+ triple acquisition push into infectious disease prevention

Lilly will acquire Curevo in a deal worth up to $1.5 billion in cash, including upfront and milestone-based payments.

Takeda Pharma ordered to pay $2.5 billion in Amitiza case

US federal jury finds Japanese drugmaker liable for anticompetitive agreement delaying generic version of constipation drug Amitiza

Roche moves to acquire PathAI for up to $1.05 billion in major AI pathology push

The acquisition positions Roche more aggressively in digital pathology and precision diagnostics capabilities

Gujarat Themis Biosyn to acquire anti-TB and anti-infective brands from Sanofi for EUR 158 Million

Deal includes 13 branded generic products across 55+ countries; acquisition expected to strengthen global anti-infective portfolio and expand regulated market presence

Merck moves to seal $53-a-share takeover of Terns Pharmaceuticals

The acquisition aims to bolster Merck’s hematology portfolio with Terns’ lead oncology candidate, TERN-701

Strides acquires generic brands from Sandoz to boost Africa business

The initial consideration for the transaction is US$ 12 million